Home / Research-Category / CBR Pharma Insights Market Research
Sort By: Title Date Price
01 Jun
2015

Biosimilars - Regulatory Framework and Pipeline Analysis

Biosimilars are copied versions of biologics that offer a 20-50% reduction in cost compared with innovative biologic products. Biosimilars are getting the world wide attention as the cost of the innovative biologics are enormously high and even minimal reduction in price will reduce the healthcare spending substantially. All the countries are focusing on reducing the healthcare expenditure and biosimilars compliments to this goal.

$2995 Read More
02 Jun
2015

Mens Health - Changing Male Attitudes to Health to Improve Prognosis and Outcomes

Men’s health refers to conditions that specifically affect males, or those that are not gender-specific but have different outcomes in men. Although still dominated by cardiovascular disease, men’s health is increasingly focusing on other conditions and the wellness of the man overall.

$2995 Read More
28 May
2015

Womens Health - Assessing the Need for a Targeted and Specialized Approach

Many of the diseases and conditions that affect mainly women are interlinked with similar root causes; however, placing all of the pieces of the puzzle together to ensure a cohesive management strategy remains a challenge. Women’s Health is a collection of multi-factorial conditions and diseases that solely affect or are more prevalent in females.

$2995 Read More
02 Jun
2015

Opioids Market Overview to 2023 - Opioids in Emerging Markets

The report provides analysis of new developments that will have a strong bearing on the use of opioids in pain management in emerging countries (Argentina, Brazil, China, India, Mexico, Russia and South Africa). Access to opioids is restricted under strict drug control policies and regulations overseeing controlled medicines due to their high abuse potential. Emphasis on restricting access to controlled drugs is much higher in emerging markets than in developed nations, resulting in a level of consumption that is too low to meet pain-control requirements even in cases of terminal illness.

$2995 Read More
29 May
2015

Opioids Market Overview to 2023 - Opioids in Western Europe

The report provides an estimation of 2013 opioid revenues and forecast consumption and revenues until 2023 in the five major Western European countries: the UK, Germany, France, Italy and Spain. The estimated revenues for 2013 are highest in the UK, which held a share of 52%, followed by Germany with 20%. Spain had the lowest in terms of both consumption (3.3%) and revenues (2.2%). Their use for medicinal purposes has been highly controversial for several decades. Although recognized as potent painkillers, potential for misuse is high. As a result, all regulatory authorities strive to maintain a fine balance between enforcing strict regulations that will crack down on illicit usage but at the same time ensure accessibility for genuine medical purposes.

$2995 Read More
03 Jun
2015

Pediatric Drug Development - Regulatory challenges and commercial opportunities

Although pediatrics represent around two-fifths of the global population the market for pediatric medicines remains relatively small (accounting for <10% of global pharmaceutical sales). Until pediatric legislation was introduced in the US (1997) and EU (2007) there has been little incentive for the pharma industry to evaluate drugs in children due to the low medical need of chronic illnesses and the high off-label use of generic drugs (Milne & Bruss, 2008).  Since the introduction of pediatric legislation there has been a substantial investment in pediatric research and the number of clinical trials performed in children has increased significantly.

$2995 Read More
01 Jun
2015

Adaptive Licensing - A Holistic Approach to Drug Development and Regulation

Adaptive Licensing (AL) is a flexible approach to drug development and regulation, with two live pilot schemes accepted by the European Medicines Agency (EMA). The system acknowledges that levels of uncertainty will always surround innovative treatments. An initial license is granted at an earlier stage than possible under the traditional system, with less clinical information from Randomized Controlled Trials (RCTs).

$2996 Read More
01 Jun
2015

Geriatric Medicine Development - Carving out New Opportunities to Treat Age-related Diseases

More than 50% of prescriptions is written for people aged 65 years and older. Many older people suffer from comorbid conditions and one in three takes at least five drugs or more on a daily basis. This significantly increases the risk of Adverse Drug Events (ADEs) and hospitalization. Up to one third of emergency admissions in elderly people is drug-related. There remains a lack of clinical data to support prescription decisions as relatively few medicines have been clinically evaluated in age-appropriate patients.

$3900 Read More
08 Apr
2015

Vaccine Development Strategies - Refocusing Efforts to Address New Challenges

Vaccines are one of the most important healthcare advances and have saved millions of lives through immunizing against some of the most deadly diseases. With protection against a number of key viral and bacterial diseases now effectively generated, vaccine R&D is turning to areas of unmet need. Preventative vaccination in adults and against pathogens that affect the developing world is increasingly becoming a focus. Research into therapeutic vaccination for patients already affected by a disease is also gathering pace.

$3900 Read More
07 May
2015

Biosimilars - Biosimilars on the cusp of a new era

The biosimilars market is undergoing rapid change with developments such as the recent approvals of infliximab and trastuzumab heralding a new era. In order to keep up with the pace of change in the marketplace, regulatory agencies have been developing updated guidance around the development and approval of biosimilars, but there is still a lack of consistency, particularly between the two leading agencies – the FDA and EMA.  Moreover, there are some concerns around biosimilar use, for example with physicians worried about how similar certain drugs are and whether they can safely be used in particular patient populations such as transplant, due to the potential for variance in efficacy and tolerability.

$2995 Read More
22 Apr
2015

Telemedicine - The Future is Now for Moving Telemedicine into Mainstream Treatment

Telemedicine is a creation of the 20th century. First used primarily for military and space applications, it has been becoming more widespread in use in recent years. There are three main types of telemedicine applications: store-and-forward, remote monitoring and interactive services. Interest in telemedicine is growing globally, particularly in the fields of teleradiology, telepathology and teledermatology. Globally, cost is seen as the major barrier to telemedicine programs. In the US, telemedicine has been promoted as a way to serve rural populations, but in the next few years it is expected to spread to a much wider patient base.

$3900 Read More
18 Feb
2015

Immunotherapy Development Strategies - An Evolving Market with Significant Potential but with Challenging Hurdles to Overcome

Although immunotherapy was first recognized over 100 years ago, it has only become an important therapeutic tool in recent decades. The immune system can be harnessed in one of several ways to tackle various diseases such as cancer, infection, auto-immune disease and inflammatory diseases. The complexity of the immune system has led to some intrinsic obstacles with clinical research, particularly in relation to targeting the right genes, identifying the appropriate patient population and accessing internal tissues for testing.

$3900 Read More
21 May
2015

The Politics of Pharma - Washington, States and the Courts Impact on the Industry

Politics have a greater direct effect on the pharmaceutical industry than almost any other in the US, and correspondingly, pharma makes considerable investments in election campaigns. The November elections kept the face of Washington the same, with the re-election of President Obama, Democratic control of the Senate and Republican control of the House. However, the outcome of the elections will still impact the industry in a variety of ways. The Medical Device Excise Tax, a component of the 2010 health care reform legislation, survived a pre-election Congressional effort at repeal, but a coalition of House Republicans and Democrats from key states are looking to try again.

$3900 Read More
05 May
2015

R&D Productivity - The State of Research and Development in the BioPharmaceutical Industry

As blockbusters go off patent and the pool of marketed products supporting pharmaceutical Research & Development (R&D) decline, questions about the future of R&D in the pharmaceutical and biotech industry arise. Where will funding come from? Is spend decreasing? If spend is decreasing, what impact is this having on R&D? What can be done to encourage innovation in the biotech and pharmaceutical industry? Is the biotech model of R&D better for innovation than the traditional pharmaceutical model? Gauging the overall growth of R&D in the pharmaceutical and biotech industry proves challenging in regards to stipulating the appropriate definition of variables by which this is measured.

$3900 Read More
09 Apr
2015

Companion Diagnostics - Streamlining drug development and advancing personalized medicine

Personalized healthcare encompasses tailored diagnostics, treatment and management of illnesses and diseases. Although the concept has been around for many years, it is only with the advent of companion diagnostics that personalized healthcare has started to gain ground. Companion diagnostics can be used in screening, monitoring, diagnosing and treating patients and can allow for stratification of patients to maximize efficacy and minimize risk

$3900 Read More
22 Apr
2015

Biopharma M&A and Deal Making - Understanding the Latest Trends to Optimize Future Strategy

The leading pharmaceutical players continue to face the combined threats of a difficult operating environment and patent losses while struggling to deliver on pipeline potential. Externalization strategies are a key means to boost future revenues and, indeed more imminently, to satisfy shareholder demands. However, the increasing size of the leading biopharmaceutical companies is necessitating their involvement in growing the numbers and size of deals year by year. This in itself, along with the rising financial firepower of the mid-tier players, has increased the level of competition for the most attractive targets.

$3900 Read More
09 Apr
2015

Oncology Development Strategies - Considerable commercial potential but specific needs must be addressed

The oncology therapeutic area has seen significant development and advances over the last decade. However, oncology has one of the lowest overall clinical success rates of all therapy areas with only a third of oncology drugs that get to Phase III proceeding to approval. There are a number of factors that will affect the likelihood of success in oncology drug development and these must be taken into consideration when designing the clinical development plan. Oncology clinical trials tend to be more complex than those in other therapy areas, largely due to the number of endpoints that can be utilized, the growing need for adaptive trial design and the types of patients that are eligible for the clinical studies.

$3900 Read More
08 Apr
2015

Biologics in the Emerging Markets - Ripe For Realization of the Commercial Potential - But Hurdles Still to Overcome

Biologics cover a diverse range of products and deliverables and have revolutionized the treatment of many diseases. The complexity of biologics has made their manufacture an expensive and lengthy process which has hindered uptake in many less developed healthcare markets. However, the global biologics market is rapidly growing and was estimated to be worth over $130 billion in 2010. Of the emerging markets, the BRIC markets offer the greatest potential for pharmaceutical growth, especially in biologics which represent a relatively untapped market in these countries. It is expected the BRIC markets will account for over 25% of global biologic revenues by 2015.

$3900 Read More
04 Mar
2015

Electronic Health Records - Charting the Future of Health Care

Electronic Health Records have been in limited use since the 1960s, but their adoption received a major boost when they became more of a focus for the US government. In 2004, President Bush put forth the goal of having every American covered by an EHR within 10 years. In 2009, President Obama added the key element of funding under the American Recovery and Reinvestment Act. The EHR Meaningful Use Incentive programs funded under the ARA were further bolstered by programs in the 2010 health care reform legislation which promoted Accountable Care Organizations. After the results of the November elections and the Supreme Courts ruling upholding the individual mandate, the future for health care reform would look more sure.

$3900 Read More
20 May
2015

The Digital Patient - A Snapshot of the Digital Landscape of Patients and Caregivers

The advent of mobile phones and other devices has opened up new channels for pharmaceutical marketers to reach patients and caregivers. The Pharma industry as a whole is late to the digital game so logically patients and caregivers have pre-existing expectations of the digital experience. Digital enables brands to deliver highly targeted information in a variety of forms. It creates the setting for a brand experience versus a promotional moment. This is a tremendous opportunity but not one without challenges one of the biggest obstacles being lack of clear direction from the FDA around appropriate use of social media.

$3900 Read More
11 Feb
2015

Emerging Pharmaceutical Technologies - Stem cells

The report, Emerging Pharmaceutical Technologies - Stem cells has been written to support corporate strategy, new product development, business development, and R&D teams through its analysis of the trends being seen and the innovations taking place in this fast moving area. This report will support the corporate strategies and key decisions being made in this area through its analysis, insights, case studies, and company profiles included.

$3900 Read More
04 Mar
2015

Accountable Care Organizations - A Building Block for the Future of Health Care

The Accountable Care Act promoted ACOs through a variety of programs: Comprehensive Primary Care Initiative, Partnerships for Patients Initiative, Pioneer and Advanced Payment ACO Models and Medicare Shared Savings Program for ACOs. The central program is the Medicare Shared Savings Program, under which ACOs gradually share in the cost savings they achieve through providing coordinated and consistent care to groups of Medicare beneficiaries while meeting quality targets. The focus of ACOs is coordinated care, ease-of-access, care management models, evidence-based care, technology use for data management, and clinical integration.

$3900 Read More
22 Apr
2015

Clinical Development and Trial Design - Developing a Coherent Approach From Beginning to End

A good clinical development plan will ensure success throughout the product lifecycle. In todays cost constrained environment, the clinical development plan can help refine the trial process, encouraging cost and time efficiencies and ensuring a streamlined process throughout. The clinical development plan ties together all aspects of product development, enabling an incorporated approach to the clinical and commercial rationale of product development. A variety of approaches should be adopted to ensure a robust clinical development plan is developed.

$3900 Read More
03 Feb
2015

Diversification in the Pharmaceutical Industry - Essential For Survival or an Unnecessary Distraction?

Pharmaceutical companies face the dual threats of industry specific difficulties driven by the innovation crisis, patent expiries and healthcare reform, coupled with the more generalized issues caused by the continuing global economic slowdown. The industry remains split on whether diversification or specialization is the key to building a successful business model in the face of these difficulties. On one hand some companies believe that diversification is necessary to survive and thrive in the current difficult operating environment and that it offers specific advantages going forward.

$3900 Read More
09 Jun
2015

The Next Generation of Pharmaceutical Marketing Strategies - Understanding All of the Strategic Considerations Needed in the Age of Multiple Stakeholders

Pharmaceuticals save lives. They prevent more serious, life changing conditions, they prevent surgery, and they improve the quality of life for many patients. The environment in which these products are developed and commercialized is in a period of great transformation. Lacking a crystal ball, the industry as a whole is navigating through unchartered waters. Multiple factors are driving the need for industry-wide change. One of the biggest contributors is the escalating cost of healthcare. In an effort to stop and reverse this trend a great emphasis is being placed on improving the delivery of care and outcomes for patients.

$3900 Read More
08 Apr
2015

Pharmaceutical Pricing Strategies - Changing approaches to meet challenging times

The current economic environment has created a number of challenges within the pharmaceutical market, with governments looking to reduce spending on healthcare and drugs. Consequently, prices have come under scrutiny, with many older products having discounts forced upon them and new drugs being subject to increasingly complex assessments in order to obtain the desired price. Novel pricing policies, such as value based pricing and external price referencing, are being employed by governments to regulate pharmaceutical prices and are expected to have a significant impact on prices and profitability in the future.

$3900 Read More
14 Apr
2015

The Payer Landscape in the United States - The Pharmaceutical Industry Faces a Rapidly Changing Marketplace

Managed care began to be developed as early as 1917, with both private and government payers established by the mid-1960s. Medicare and Medicaid are the major government payers, with the health care reform legislation of 2010 providing changes for both. That said, private payers, such as regionals, nationals and blues plans, may take the brunt of the reform policies put in place. The health care reform legislation in 2010 was the product of extended debate and compromise. The legislation will mean huge changes for the insurance industry if it is enacted. However, the more controversial aspects of the legislation, particularly the Mandate for health insurance, have resulted in numerous challenges.

$3900 Read More
08 Apr
2015

Reformulation Strategies - New Technologies Extend Use Beyond Lifecycle Management

Reformulation performs a key role in the pharmaceutical industry enabling companies to maximize their returns on investment while broadening treatment options and improving patient experience. Its potential to rejuvenate R&D pipelines in the future as new technologies emerge compliment its position as a key lifecycle management strategy. Reformulation will continue to be a much used lifecycle management strategy, enabling companies to boost sales before patent expiry and in ideal cases protect sales after generics enter. However in order to achieve this companies must focus increasingly on demonstrating provable benefits, ideally in head to head trials against the original product.

$3900 Read More
20 May
2015

Looking at Senior Long-term Care - Where will the market go?

In the last 50 years, long-term care facilities in the US have changed significantly. Many facilities are now Continuing Care Retirement Communities (CCRCs), offering a continuum of care from Independent Living to Assisted Living to Skilled Nursing. Memory Care facilities, for those with Alzheimers Disease or Dementia are often separate facilities, but may be part of a larger CCRC campus. Long-term care is becoming increasingly important as a market with the US population aging. Over 65s are now the fastest growing population group in the US. With the Baby Boomer generation only just beginning to turn 65 in 2011, the next 20 years will see tremendous growth in the long-term care population.

$3900 Read More
07 Apr
2015

Risk Evaluation and Mitigation Strategies - Adaptation in an evolving system

As an evolution of this process, the agency established the Risk Evaluation and Mitigation Strategies (REMS) program in 2008. Products can be approved with a Medication Guide only REMS, a Communication Plan REMS which incorporates a Medication Guide together with educational materials for providers or it can require Elements to Assure Safe Usage (ETASU). There has been substantial criticism of the current REMS system from pharmaceutical companies, as well as from providers and dispensers. The FDA is moving to address some of these criticisms by trying to establish greater standardization across the system.

$3900 Read More
02 Jul
2015

Life Cycle Management Strategies - Optimizing revenues and defending generic competition

GBI Research’s latest report, ""Life Cycle Management Strategies - Optimizing revenues and defending generic competition"" discusses various stages of product lifecycle management (LCM), Developmental, commercial and legal LCM strategies, objectives, benefits, factors impacting the choice of lifecycle management strategies, and keys to successful implementation of the strategies.

$2995 Read More
10 Nov
2015

Opioids Overview to 2021 - An Assessment of Pain Management and Dependence

GBI Research’s latest report, ""Opioids Overview to 2021 - An Assessment of Pain Management and Dependence"" discusses the use of opioids as potent analgesics for the treatment of cancer and non-cancer pain and examines the management of opioid dependence in the US, the UK, Germany, Spain, Italy, France, Australia, Japan, India and China.

$2995 Read More
15 Sep
2015

Gene Therapies: A Diverse Range of Technologies with a Promising Long-Term Outlook

GBI Research’s latest report, "Gene Therapies: A Diverse Range of Technologies with a Promising Long-Term Outlook" discusses all gene therapies under the broad criteria of genetic material introduced to the cell for a therapeutic purpose. It includes not only the insertion of a gene into the cell for expression, but also gene silencing with RNA interference (RNAi) and antisense RNA, aptamers (DNA or RNA polymers which bind to a protein target), and oncolytic viruses.

$2995 Read More
02 Dec
2015

Biobanking: Developing Smart, Sustainable and Ethically Compliant Biorepositories for the Future

GBI Research’s latest report, ""Biobanking: Developing Smart, Sustainable and Ethically Compliant Biorepositories for the Future"" discusses fundamental concepts in biobanking and recent technology advancements in the field. The report also describes ethical and regulatory concerns in biobanking as well as the economic challenges and opportunities surrounding this industry.

$2995 Read More
13 Feb
2016

Evolving Market Access Strategies - Pricing and Reimbursement Landscape in Major Developed Pharmaceutical Markets

GBI Research's latest report, ""Evolving Market Access Strategies - Pricing and Reimbursement Landscape in Major Developed Pharmaceutical Markets"" assesses developments within the key elements of market access such as Health Economics and Outcome Research (HEOR), Health Technology Assessment (HTA) as well as pricing and reimbursements strategies for pharmaceutical products.

$2995 Read More
01 Mar
2016

Telehealth: Global Market Trends, Regulatory Landscape and Operational Strategies

GBI Research's latest report, ""Telehealth: Global Market Trends, Regulatory Landscape and Operational Strategies"", provides key insights into the global telehealth regulatory and market landscape, as well as its main applications in healthcare and associated sectors.

$2995 Read More
01 May
2016

Human Drugs For Veterinary Use - Current Trends and Future Commercial Prospects for Crossover Drugs

GBI Research's latest report, ""Human Drugs For Veterinary Use - Current Trends and Future Commercial Prospects for Crossover Drugs"", discusses global commercial trends and prospects for human medicines applied in the veterinary setting, also called crossover drugs. A wide range of human drugs continue to be applied in the veterinary space due to a lack of approved animal therapies, convenience and the rising costs of veterinary research.

$2995 Read More
01 Jun
2016

Innovation Tracking Factbook 2016 - An Assessment of the Pharmaceutical Pipeline

GBI Research’s latest report, ""Innovation Tracking Factbook 2016 - An Assessment of the Pharmaceutical Pipeline"" is a comprehensive, granular analysis of the 20,756 products currently in the pharmaceutical industry pipeline, from the Discovery stage through to Pre-registration and split into therapy areas and key indications. This pipeline is also benchmarked against its size across each segment in 2015, and an assessment of the level of first-in-class innovation is provided. In addition, a detailed contextual analysis of the key drivers of this pipeline is provided, in addition to an assessment of companies present in the pipeline and historical deal value and volume.

$2995 Read More
01 Jul
2016

Stem Cell Therapies - Global Trends in the Competitive, Technological and R&D Landscape

GBI Research’s latest report, ""Stem Cell Therapies - Global Trends in the Competitive, Technological and R&D Landscape"" provides an in-depth assessment of the current trends in the global stem cell therapy sector with a particular focus on the technological, competitive and R&D landscape.

$2995 Read More
28 Apr
2017

Global Carbon Toroidal Nanotube Industry 2017, Trends and Forecast Report

Carbon Toroidal Nanotube Report by Material, Application, and Geography Global Forecast to 2021 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China).

$2850 Read More
23 Nov
2017

Monoclonal Antibodies Market Global Trends in the Competitive Technological and R&D Landscape

GBI Research’s latest report, CBR Monoclonal Antibodies: Global Trends in the Competitive, Technological and R&D Landscape, discusses both the pipeline and market shares of monoclonal antibodies (mAbs) across a number of therapy areas. mAbs are defined as a collection of antibodies produced from a single B-cell clone.

$2995 Read More
30 Dec
2017

Nutraceuticals: New Applications for Probiotics, Genetic Modification and Diet as Products Make Gains in Rx Territory

The nutraceuticals market is growing and diversifying rapidly. These products are linked by the fact that they are dietary products that have some degree of either purported or clinically evidenced medical benefit. However, the market lacks a clear definition of what constitutes a nutraceutical, with the term covering a spectrum of products from prescription-only medical foods to widely available consumer supplements.

$2995 Read More